Zealand Pharma convenes its Annual General Meeting 2018

| Source: Zealand Pharma Zealand Pharma

Company Announcement - No. 10/2018

Zealand Pharma convenes its Annual General Meeting 2018

Copenhagen, March 22, 2018 - Zealand Pharma A/S ("Zealand") convenes the Company's ordinary Annual General Meeting to be held on
 
Thursday April 19, 2018 at 3.00 pm CET
 
at the offices of Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø, Denmark.
 
Agenda:
 
  1. Management's report on the Company's activities during the past financial year
  1. Approval of the audited Annual Report 2017
 
  1. Resolution on the distribution of profit or the cover of loss in accordance with the approved Annual Report 2017
 
  1. Election of members to the Board of Directors
 
  1. Election of the auditor
 
  1. Authorization for the Company to acquire treasury shares directly and/or acquire American depositary shares
 
  1. Proposal from the Board of Directors to update the Company's Remuneration Policy and the Overall Guidelines for Incentive pay to the Executive Management of Zealand Pharma A/S
 
  1. Proposal by the Board of Directors to approve the fees for the Board of Directors for the financial year 2018
 
  1. Proposal by the Board of Directors to dissolve the Shareholder Nomination Committee, including proposal to delete Section 15 of the Company's Articles of Association
 
  1. Proposal by the Board of Directors to amend the Company's Articles of Association, including (i) amendment of Section 5.8 to reflect the CVR no. of Computershare A/S, (ii) deletion of expired paragraphs in Section 8.1, (iii) update of the name of the Danish Business Authority in Section 9.2 and 9.8, (iv) amendment of Section 9.16 to ensure consistency between the Danish and English version of this Section and (v) deletion of the used authorization on electronic communication in Section 12.5 and (vi) deletion of Section 13.3 regarding retirement age for members of the Board of Directors
 
  1. Proposal from the Board of Directors to approve a new authorisation to increase the capital of the Company
 
  1. Any other business
 
The Annual General Meeting will be held in English.

 

After the Annual General Meeting 2018, refreshments (coffee and cake) will be served, and there will be an opportunity to speak with members of Zealand's Corporate Management team.

 

The notice to convene the Annual General Meeting as well as the registration and proxy forms are available on Zealand's website via the following link:
www.zealandpharma.com/annual-general-meeting/

 

The notice to convene is enclosed to this announcement, and the following should be noted:

 
Agenda item no. 4: The board members elected by the General Meeting are elected on an annual basis. All of the incumbent board members are standing for re-election, and the Nomination Committee proposes the re-election of all the members:

 

  • Rosemary Crane
  • Catherine Moukheibir
  • Alain Munoz
  • Martin Nicklasson
  • Michael J. Owen
 

In addition the Nomination Committee proposes the election of an additional independent member of the Board of Directors:

 

  • Kirsten Aarup Drejer
 

For a description of the nominated candidates, see Appendix 1 to this notice.
 

For further information, please contact:

Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of proprietary medicines in late-stage clinical development focused on specialty gastrointestinal and metabolic diseases. In addition, Zealand has two marketed drugs under license to Sanofi and two compounds in clinical development under license to Boehringer Ingelheim.

Attachments

10-18_0322 Notice to convene AGM